GcMAF, the most powerful of the immunotherapies, is the best treatment yet found for cancer. In our clinics 77% of terminal stage 4 cancer patients receive an average 25% tumour reduction in a week, and instead of dying, we send them home recovering.
GcMAF is a human protein and a human right. It has no side effects. It is the lowest risk strategy you can adopt.
It successfully treats 50 other diseases including kidney, hepatitis B and C, autism and cirrhosis of the liver.
300 scientists have written 150 research papers on GcMAF. Some are linked below.
Cancer research papers
16 nonanemic prostate cancer patients received weekly administration of 100 ng of GcMAF. After 14 to 25 weekly administrations of GcMAF (100 ng/week), all 16 patients had levels equivalent to those of healthy control values, indicating that these patients are tumor-free. No recurrence occurred for 7 years.
Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto: GcMAF, Translational Oncologie: Vol 1, No 2: 65-72 (2008a)
Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). After about 16-22 administrations (approximately 3.5-5 months) of GcMAF, these patients had insignificantly low serum enzyme levels indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years.
Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto, Naofumi Ushijima: International Journal of Cancer 122: 461-467 (2008b)
After 32–50 weekly administrations of 100 ng GcMAF, all colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells. During 7 years after the completion of GcMAF therapy, their serum Nagalase activity did not increase, indicating no recurrence of cancer, which was also supported by the annual CT scans of these patients.
Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto, Naofumi Ushijima:
On the effects of GcMAF in human breast cancer cells in vitro. GcMAF reverts the neoplastic phenotype; cancer cells become normal and are deprived of their metastatic potential.
Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M. Anticancer Res. 2012 Jan;32(1):45-52.
GcMAF activates macrophages that attack and destroy human breast cancer cells. The molecular assembly and mode of action of GcMAF are elucidated. For the first time an interconnection with the vitamin D receptor (VDR) signalling is presented.
Thyer L, Ward E, Smith R, Fiore MG, Magherini S, Branca JJ, Morucci G, Gulisano M, Ruggiero M, Pacini S. Nutrients. 2013 Jul 8;5(7):2577-89. doi: 10.3390/nu5072577.
On the therapeutic effects of GcMAF in 20 patients with advanced cancer defined as incurable. Clinical cases of breast, prostate, bladder, ovarian, colon, tongue, larynx, head and neck carcinomas, lymphomas and oligodedroglioma
Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D, Eslinger R, Pacini S. OncoImmunology 2013; 2:e25769; .
On the multifaceted effects of GcMAF in human breast cancer cells and human neuroblastoma (a brain tumour) cells. Here it is demonstrated that when GcMAF is prepared according to its molecular configuration, it is 100 fold more effective than “regular” GcMAF in destroying human cancer cells.
Ruggiero M, Pacini S, Morucci G, Branca J, Ward E, Smith RJ, Thyer L and Gulisano M (2013). Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00221.
These results are consistent with the hypothesis that the known anticancer efficacy of DBP-MAF can be ascribed to different biological properties of the molecule that include inhibition of tumour-induced angiogenesis and direct inhibition of cancer cell proliferation, migration and metastatic potential.
M. Ruggiero, M.G. Fiore, S. Magherini, G. Morucci, J.J.V. Branca, M. Gulisano, L. Thyer, S. Pacini. Abstr.
GcMAF has a significant therapeutic effect in 20 patients with advanced cancer. These results are presented at the 67th National Congress of the Italian Society of Anatomy and Histology.
Gulisano M, Pacini S, Thyer L, Morucci G, Branca JJV, Smith R, Wards E and Noakes D. (P85). Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S104.
Other potential therapeutic effects of GcMAF
GcMAF increases energy production at the mitochondrial level. These results explain the reported increase of energy observed by patients treated with GcMAF for different diseases.
Pacini S, Morucci G, Branca JJ, Aterini S, Amato M, Gulisano M, Ruggiero M. Nutrients. 2013 Jun 7;5(6):2076-92. doi: 10.3390/nu5062076.
On the therapeutic effects of GcMAF in patients with cancer, autism, chronic fatigue syndrome, Lyme disease, multiple sclerosis, amyotrophic lateral sclerosis. This is the first report on the therapeutic effects of GcMAF in patients with these dreadful neurological diseases.
Lynda Thyer, Emma Ward, Rodney Smith, Jacopo J.V. Branca, Gabriele Morucci, Massimo Gulisano, David Noakes and Stefania Pacini. DOI : 10.3844/ajisp.2013.78.84. American Journal of Immunology. Volume 9, Issue 3
On the therapeutic effects of GcMAF in autism. Autism is eradicated in a significant percentage of cases. About 85% of subjects show improvement following GcMAF treatment.
James Jeffrey Bradstreet, emar Vogelaar and Lynda Thyer. Autism Insights 2012:4 31–38. doi: 10.4137/AUI.S10485.
Since latently HIV-infected cells are unstable and constantly release HIV virions, the activated macrophages rapidly intercept the released HIV virions to prevent reinfection resulting in exhaustion of infected cells. After less than 18 weekly administrations of 100 ng GcMAF for nonanemic patients, they exhibited low serum Nagalase activities equivalent to healthy controls, indicating eradication of HIV-infection, which was also confirmed by no infectious center formation by provirus inducing agent-treated patient PBMCs. No recurrence occurred and their healthy CD + cell counts were maintained for 7 years.
Nobuto Yamamoto, Naofumi Ushijima, Yoshihiko Koga: Journal of Medical Virology 81:16–26 (2009)
The effects of GcMAF on human neurons explain its therapeutic effects in autism, chronic fatigue syndrome, multiple sclerosis and amyotrophic lateral sclerosis.
Morucci G, Fiore MG, Magherini S, Branca JJV, Gulisano M, Thyer L, Ruggiero M and Pacini S
GcMAF has a neuro-protective effect against heavy metal-induced neuronal damage. Implications for autism and chronic fatigue syndrome treatment.
Morucci G, Branca JJV, Ruggiero M, Gulisano M and Pacini S. (P29). Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S144.
GcMAF is able to increase the viability and the metabolism of human neurons, and, most important, to induce neurons to establish contact with each other. As it is well known in the field of neurosciences, a decreased connectivity among neuronal circuits is at the basis of most, if not all, neurological and neurodevelopmental disorders. The paper also explains why GcMAF combats pain.
Toxicology studies of GcMAF
The performed pre‐clinical toxicology studies of human Gc globulin in mice, rats, guinea pigs, rabbits and Shetland ponies showed no toxic effects. In beagle dogs receiving a daily dose of 20 mg/kg Gc globulin intravenous for 14 days, clinical as well as histological immunological reactions caused by production of antibodies against human Gc globulin and immune complex formation were observed.
Future studies will hopefully show whether administration of Gc globulin to patients with severe tissue injuries such as trauma, liver failure and sepsis will be able to reduce the patient’s risk of developing hypercoagulation, shock and multiple organ failure.
Pihl, Joergensen, Santoni-Rugiu, Leifsson, Hansen, Laursen, Houen: Basic & Clinical Pharmacology & Toxicology, 2010, Vol 107, pp 853-60.